Pamdeca LLC

Immuno-modulatory synthetic peptides: a novel class of drugs for immuno-oncology

  • Stage Product In Development
  • Industry Biotechnology
  • Location Newton, MA, US
  • Currency USD
  • Founded January 2015
  • Employees 3
  • Incorporation Type LLC
  • Website pamdeca.com

Company Summary

A preclinical stage immuno-oncology start-up pursuing a novel approach - activation of the natural cancer-killing program in macrophages. Our first-in-class drugs will complement and enhance immune checkpoint inhibitors - the new immuno-oncology drugs giving hope to terminal cancer patients, but hampered by low response rates and rapid development of resistance to therapy. Our innovative IP is licensed from Northwestern University.

Team

  • Victor Shifrin
    CEO

    20+ years of R&D/clinical development/management in oncology and inflammation;
    Eisai USA, Scriptgen, Surface Logix, CombinatoRx.

  • Jack Henkin
    CSO

    20+ years of drug development;
    Anticancer Peptides Project Leader at Abbott, Abbott’s Scientist of the Year, 2003;
    100+ scientific papers, reviews, and book chapters;
    Co-inventor of IP.

  • Olga Volpert
    Head of R&D

    20+ years of cancer research;
    Internationally recognized expert on cancer biology, angiogenesis, and tumor microenvironment;
    88 publications (Science, Nature Medicine, Cancer Cell, Cancer Research);
    Co-inventor of IP.

Advisors

  • Andrew Mazar, BD Advisor
    Unconfirmed

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free